SI3416983T1 - Protitelesa za IL-17C - Google Patents

Protitelesa za IL-17C

Info

Publication number
SI3416983T1
SI3416983T1 SI201730777T SI201730777T SI3416983T1 SI 3416983 T1 SI3416983 T1 SI 3416983T1 SI 201730777 T SI201730777 T SI 201730777T SI 201730777 T SI201730777 T SI 201730777T SI 3416983 T1 SI3416983 T1 SI 3416983T1
Authority
SI
Slovenia
Prior art keywords
antibodies
Prior art date
Application number
SI201730777T
Other languages
English (en)
Inventor
Jan Dominik Haas
Jurgen Klattig
Nick Ernest Rene Vandeghinste
Original Assignee
Morphosys Ag
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag, Galapagos Nv filed Critical Morphosys Ag
Publication of SI3416983T1 publication Critical patent/SI3416983T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI201730777T 2016-02-19 2017-02-17 Protitelesa za IL-17C SI3416983T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16156582 2016-02-19
EP16156651 2016-02-22
PCT/EP2017/053592 WO2017140831A1 (en) 2016-02-19 2017-02-17 Antibodies for il-17c
EP17705873.2A EP3416983B1 (en) 2016-02-19 2017-02-17 Antibodies for il-17c

Publications (1)

Publication Number Publication Date
SI3416983T1 true SI3416983T1 (sl) 2021-08-31

Family

ID=58057136

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730777T SI3416983T1 (sl) 2016-02-19 2017-02-17 Protitelesa za IL-17C

Country Status (32)

Country Link
US (4) US20190048071A1 (sl)
EP (1) EP3416983B1 (sl)
JP (2) JP6535139B2 (sl)
KR (1) KR20180109977A (sl)
CN (1) CN108699143B (sl)
AU (1) AU2017219837B2 (sl)
BR (1) BR112018016798A2 (sl)
CA (1) CA3014842A1 (sl)
CL (1) CL2018002340A1 (sl)
CO (1) CO2018008724A2 (sl)
CU (1) CU20180087A7 (sl)
CY (1) CY1124296T1 (sl)
DK (1) DK3416983T3 (sl)
EA (1) EA037813B1 (sl)
EC (1) ECSP18070641A (sl)
ES (1) ES2877376T3 (sl)
HR (1) HRP20211059T1 (sl)
HU (1) HUE054755T2 (sl)
IL (1) IL260733B2 (sl)
LT (1) LT3416983T (sl)
MA (2) MA43088B1 (sl)
MD (1) MD3416983T2 (sl)
MX (1) MX2018009860A (sl)
PH (1) PH12018501739A1 (sl)
PL (1) PL3416983T3 (sl)
RS (1) RS62012B1 (sl)
SG (1) SG11201806161TA (sl)
SI (1) SI3416983T1 (sl)
TN (1) TN2018000289A1 (sl)
TW (1) TW201734041A (sl)
WO (1) WO2017140831A1 (sl)
ZA (1) ZA201806249B (sl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2018000289A1 (en) * 2016-02-19 2020-01-16 Galapagos Nv Antibodies for il-17c
TW201919698A (zh) 2017-09-25 2019-06-01 德商莫菲西斯公司 異位性皮炎之治療
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
TW202011995A (zh) * 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
IL138930A0 (en) * 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
PT1144607E (pt) 1999-07-20 2009-04-22 Morphosys Ag Novos métodos para apresentar (poli)peptídeos/ proteínas em partículas bacteriofágicas através de ligações dissulfureto
JP2005512044A (ja) 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 結合特性に基づく抗体分類
CA2584078A1 (en) 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation
CA2624763A1 (en) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
WO2008049070A2 (en) 2006-10-18 2008-04-24 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
TW201307385A (zh) * 2010-10-25 2013-02-16 Genentech Inc 胃腸炎症和銀屑病以及哮喘的治療
PL2640742T3 (pl) 2010-11-19 2019-01-31 Morphosys Ag Kolekcja sekwencji przeciwciał i jej zastosowanie
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP3360897A1 (en) * 2011-10-19 2018-08-15 MorphoSys AG Antagonists of il17c for the treatment of inflammatory disorders
ES2685553T3 (es) 2012-06-12 2018-10-09 Orega Biotech Antagonistas de isoformas de IL-17 y sus usos
JP6944747B2 (ja) * 2014-12-15 2021-10-06 モルフォシス・アーゲー Il−17cに対する抗体
TN2018000289A1 (en) 2016-02-19 2020-01-16 Galapagos Nv Antibodies for il-17c

Also Published As

Publication number Publication date
BR112018016798A2 (pt) 2018-12-26
CO2018008724A2 (es) 2018-08-31
MA44227B1 (fr) 2021-06-30
LT3416983T (lt) 2021-07-12
AU2017219837A1 (en) 2018-08-09
MD3416983T2 (ro) 2021-08-31
JP6535139B2 (ja) 2019-06-26
EP3416983B1 (en) 2021-04-07
TW201734041A (zh) 2017-10-01
TN2018000289A1 (en) 2020-01-16
US10259869B2 (en) 2019-04-16
KR20180109977A (ko) 2018-10-08
CA3014842A1 (en) 2017-08-24
CY1124296T1 (el) 2022-11-25
EA037813B1 (ru) 2021-05-24
WO2017140831A1 (en) 2017-08-24
SG11201806161TA (en) 2018-08-30
US10633439B2 (en) 2020-04-28
JP2019511910A (ja) 2019-05-09
PL3416983T3 (pl) 2021-10-25
CN108699143B (zh) 2021-11-09
US20200216529A1 (en) 2020-07-09
ECSP18070641A (es) 2018-10-31
US11987621B2 (en) 2024-05-21
MA44227A (fr) 2018-12-26
EA201891594A1 (ru) 2019-01-31
US20190202906A1 (en) 2019-07-04
EP3416983A1 (en) 2018-12-26
AU2017219837B2 (en) 2023-08-17
CL2018002340A1 (es) 2018-11-23
JP6916834B2 (ja) 2021-08-11
JP2019162119A (ja) 2019-09-26
US20190048071A1 (en) 2019-02-14
MA43088B1 (fr) 2020-10-28
PH12018501739A1 (en) 2019-06-10
MX2018009860A (es) 2019-03-28
IL260733A (sl) 2018-09-20
US20180340024A1 (en) 2018-11-29
CN108699143A (zh) 2018-10-23
CU20180087A7 (es) 2019-03-04
HUE054755T2 (hu) 2021-09-28
ZA201806249B (en) 2020-02-26
IL260733B1 (en) 2023-11-01
IL260733B2 (en) 2024-03-01
MA43088A1 (fr) 2019-05-31
DK3416983T3 (en) 2021-06-21
ES2877376T3 (es) 2021-11-16
RS62012B1 (sr) 2021-07-30
HRP20211059T1 (hr) 2021-10-01

Similar Documents

Publication Publication Date Title
ZA201900373B (en) Anti-tim-3 antibodies
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
GB201521393D0 (en) Antibodies
GB201521391D0 (en) Antibodies
GB201521382D0 (en) Antibodies
GB201610044D0 (en) Antibodies
GB201603291D0 (en) Antibodies
GB201508180D0 (en) Antibodies
ZA201704704B (en) Antibodies for il-17c
ZA201806249B (en) Antibodies for il-17c
IL264262A (en) Antibodies against interleukin 22 receptors
GB201616699D0 (en) Antibodies
GB201509907D0 (en) Antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
GB201503438D0 (en) Antibodies
PT3416983T (pt) Anticorpos para il-17c
GB201622197D0 (en) Antibodies
GB201620414D0 (en) Antibodies
GB201615224D0 (en) Antibodies
GB201613158D0 (en) Antibodies
GB201612437D0 (en) Anti-lag-3 antibodies
GB201518728D0 (en) Antibodies
GB201515572D0 (en) Anti-LAG-3 antibodies